A Step Toward a UTI Treatment That Could Thwart Bacterial Drug Resistance


This spring, a Pennsylvania woman who developed a urinary tract infection (UTI) became the first patient in the U.S. reported to have a bacterial infection resistant to colistin, an antibiotic of last resort. The case set off alarm bells in the medical field. Now scientists report in ACS' Journal of Medicinal Chemistry a new class of small molecules for fighting the common infection. The way the molecules work could potentially prevent bacteria from developing resistance.

Millions of women in the U.S. every year suffer from UTIs. Antibiotics can treat this painful condition, but with the rise of drug-resistant bacteria, scientists are searching for alternative approaches. James W. Janetka and colleagues' strategy is to develop therapeutic molecules that prevent the bacteria that cause UTI from latching on to key cells on the lining of the urinary tract. Unlike antibiotics, which aim to kill the bacteria, these molecules interfere with the function of a critical factor, FimH, that UTI-causing bacteria make and put on their surface, enabling them to stick to the bladder lining. Such an approach would likely make it more difficult for bacteria to find a workaround. Several teams have designed molecules called O-mannosides that can bind the bacteria, but in animal testing, the compounds appeared to break down too quickly. Janetka's group wanted to address this limitation.

The researchers replaced molecular bonds in O-mannosides with carbon-based linkers to create more stable versions called C-mannosides. Testing in animal models of UTI showed that C-mannosides were more effective at fighting infections than O-mannosides. Ongoing preclinical studies will identify which C-mannoside will move into clinical trials. The resulting candidate could become the first therapeutic treatment against this type of infection, with the potential to thwart bacteria's ability to develop resistance, the researchers say.

The authors acknowledge funding from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Allergy and Infectious Diseases.

Source:  American Chemical Society

Related Videos
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Rare Disease Month: An Infection Control Today® and Contagion® collaboration.
Vaccine conspiracy theory vector illustration word cloud  (Adobe Stock 460719898 by Colored Lights)
Rare Disease Month: An Infection Control Today® and Contagion® collaboration.
Infection Control Today Topic of the Month: Mental Health
Related Content